Phase 1 · NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- ClinicalTrials.gov ID
- NCT06039826
- Indication
- Overweight
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 46
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Ethinyl Estradiol; Drug: Drospirenone
- Comparator
- Not reported
- Eligible ages
- 40 Years – 60 Years
- Locations
- 2 sites · United States
- Study start
- 12 Sept 2023
- Primary completion
- 11 Jul 2024
- Study completion
- 11 Jul 2024
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 26 Jul 2024
Endpoints
Primary
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol; PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol; PK: Time of Maximum Observed Concentration (Tmax) of Ethinyl Estradiol; PK: Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Drospirenone; PK: Maximum Observed Concentration (Cmax) of Drospirenone; PK: Time of Maximum Observed Concentration (Tmax) of Drospirenone